PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

Abstract

BACKGROUND AND PURPOSE:

PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer 89Zr-cetuximab and to assess tumour uptake.

METHODS:

Two dose schedules were used; two consecutive doses of 60MBq 89Zr-cetuximab or a single dose of 120MBq, both preceded by 400mg/m2 of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.

RESULTS:

Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of 89Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR)>1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals>5days after injection.

CONCLUSIONS:

Both presented 89Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60MBq, with a minimum time interval for scanning of 6days.

• Authors: Judith van Loon, Aniek J G Even, Hugo J W L Aerts, Michel Öllers, Frank Hoebers, Wouter van Elmpt, Ludwig Dubois, Anne-Marie C Dingemans, Roy I Lalisang, Pascal Kempers, Boudewijn Brans, Véronique Winnepenninckx, Ernst-Jan Speel, Eric Thunnissen, Kim M Smits, Ronald Boellaard, Danielle J Vugts, Dirk De Ruysscher, Philippe Lambin
• Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Radiother Oncol) Vol. 122 Issue 2 Pg. 267-273 (02 2017) ISSN: 1879-0887 [Electronic] Ireland
• PMID: 28012793 (Publication Type: Clinical Trial, Phase I, Journal Article)
• Copyright: Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Zirconium
• ErbB Receptors
• Cetuximab

Topics

• Aged
• Antineoplastic Agents (metabolism)
• Carcinoma, Non-Small-Cell Lung (diagnostic imaging, drug therapy)
• Cetuximab (metabolism)
• ErbB Receptors (analysis)
• Female
• Head and Neck Neoplasms (diagnostic imaging, drug therapy)
• Humans
• Lung Neoplasms (diagnostic imaging, drug therapy)
• Male
• Middle Aged
• Positron-Emission Tomography (methods)
• Zirconium